Lepu Biopharma Co., Ltd. (HKG: 2157) announced NMPA IND approval for a groundbreaking Phase II/III clinical trial evaluating Becotatug Vedotin (MRG003) in combination with Pucotenlimab (HX008) for the perioperative treatment of locally advanced, resectable head and neck squamous cell carcinoma (HNSCC) – marking the world’s first study to explore an EGFR ADC + PD‑1 monoclonal antibody combination in the curative‑intent, early‑stage setting vs. traditional late‑line metastatic therapy.
Regulatory Milestone
Item
Detail
Agency
NMPA (China)
Trial Status
IND approved – clinical trial initiation authorized
Company
Lepu Biopharma Co., Ltd. (HKG: 2157)
Combination
Becotatug Vedotin (MRG003) + Pucotenlimab (HX008)
Indication
Perioperative treatment of locally advanced, resectable HNSCC
Global Significance
First study worldwide exploring EGFR ADC + PD‑1 in perioperative HNSCC
Paradigm Shift
From late‑line metastatic therapy to early‑stage perioperative intervention
Dual mechanism targeting both tumor cell killing and anti‑tumor immunity
Global Uniqueness
No prior EGFR ADC + PD‑1 perioperative data
First‑in‑world exploration of this combination paradigm
Market Impact & Outlook
HNSCC Market Dynamics: Head and neck cancer affects ~650,000 patients globally annually; 60‑70% present with locally advanced disease; standard of care (surgery + chemoradiation) yields 5‑year survival 40‑50% with high recurrence rates; perioperative immunotherapy (KEYNOTE‑689) recently validated, but EGFR ADC addition represents novel intensification strategy.
EGFR Targeting Rationale: EGFR overexpressed in >90% of HNSCC; cetuximab (EGFR mAb) approved but limited by lack of cytotoxic payload; Becotatug Vedotin’s MMAE payload adds direct tumor cell killing to EGFR blockade; potential for superior pathologic complete response (pCR) rates vs. immunotherapy alone.
Pucotenlimab Differentiation: Extended half‑life PD‑1 design supports convenient dosing schedule (potentially Q4‑6W vs. standard Q2‑3W); reduced injection burden critical for perioperative patient compliance; Hansoh/Lepu co‑development leverages combined commercial infrastructure for China launch.
Clinical Development Trajectory: Phase II neoadjuvant pCR assessment 2026‑2027; Phase III event‑free survival (EFS) primary endpoint 2028‑2030; perioperative immunotherapy standard established by pembrolizumab (KEYNOTE‑689) creates regulatory precedent for accelerated approval based on pCR/EFS.
Competitive Positioning: First‑mover in EGFR ADC + PD‑1 perioperative space vs. Merck (pembrolizumab monotherapy), BMS (nivolumab), and emerging TIGIT/LAG‑3 combinations; potential for China‑first approval with global Phase III expansion; partnership opportunity with global pharma for ex‑China rights upon Phase II data.
Forward‑Looking Statements This brief contains forward‑looking statements regarding clinical development timelines, perioperative efficacy expectations, and commercial potential for the Becotatug Vedotin + Pucotenlimab combination in HNSCC. Actual results may differ due to surgical complication risks, neoadjuvant toxicity management challenges, and competitive dynamics in the evolving perioperative immunotherapy landscape.-Fineline Info & Tech
By Fineline Cube 